Tech Company Financing Transactions
Immunome Funding Round
Immunome, based in Exton, secured $5 million from private investors.
Transaction Overview
Company Name
Announced On
5/31/2017
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 48 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
665 Stockton Dr. 300
Exton, PA 19341
USA
Exton, PA 19341
USA
Phone
Website
Email Address
Overview
Immunome (Nasdaq: IMNM) is a biopharmaceutical company with a patented native, human antibody platform which enables us to harness the natural curative power of the human immune system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Purnanand Sarma
Chief Scientific Officer
Michael Morin
Co-Founder
Scott Dessain
VP - Bus. Development
Karen Lundgren
VP - Engineering
Pavel Nikitin
VP - R & D
Lauren Pitt
VP - R & D
Matthew Robinson
Browse more venture capital transactions:
Prev: 5/31/2017: People.ai venture capital transaction
Next: 5/31/2017: CounterTack venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs